Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer
(NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of …

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand
binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent …

Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

Objectives Adenocarcinoma (ADC) to squamous cell carcinoma (SCC) transformation (AST)
is reported in epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer …

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has
undergone rapid changes with innovations in oncogene-directed therapy and immune …

Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …

Abstract Introduction Squamous cell cancer (SqCC) is a lung cancer subtype with few
targeted therapy options. Molecular characterization, that is, by next-generation sequencing …

Sonoporation is a drug and gene delivery system using ultrasonication that allows the
intracellular delivery of foreign molecules that cannot enter cells under normal conditions …